JAK  inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus | Zendy

Klaeschen Anna Sophie | Zendy; Wolf Dominik | Zendy; Brossart Peter | Zendy; Bieber Thomas | Zendy; Wenzel Joerg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus

Author(s) -

Klaeschen Anna Sophie,

Wolf Dominik,

Brossart Peter,

Bieber Thomas,

Wenzel Joerg

Publication year - 2017

Publication title -

experimental dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.108

H-Index - 96

eISSN - 1600-0625

pISSN - 0906-6705

DOI - 10.1111/exd.13253

Subject(s) - ruxolitinib , tofacitinib , lupus erythematosus , medicine , immunology , systemic lupus erythematosus , cancer research , myelofibrosis , rheumatoid arthritis , antibody , disease , bone marrow

This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK 1/2‐kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho‐ JAK 2 in CLE skin samples as well as the immunomodulatory in vitro effect of ruxolitinib in cultured immortalized keratinocytes and in a 3D human epidermis model (epi CS ). Our results demonstrate that ruxolitinib significantly decreases the production of CLE ‐typical cytokines ( CXCL 10, CXCL 9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research